Cancer Family
Childhood Neoplasm
CI-CAN-00000009Explore in graph →
PediatricNon-malignant312 active trials1 approved drugs68 evidence items
- NCIt
- C6283
Loading cancer entity…
Cancer Family
CI-CAN-00000009Explore in graph →
Clinical trials
1,503 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00505063 | Prospective Trial of Vaccine Responses in Childhood Cancer Survivors | completed | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04479514 | Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy | completed | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT00107198 |
| Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease |
| completed |
| Phase 2 |
| 188 |
| Children's Oncology GroupNETWORK |
| 6 |
| Jun 5, 2026 |
| clinicaltrials |
| NCT02220985 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | completed | Phase 2 | 84 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT05148078 | Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE) | completed | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05466994 | A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT04738162 | Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors | completed | Phase 2 | 78 | Universität MünsterOTHER | 2 | Dec 10, 2025 | clinicaltrials |
| NCT01602666 | Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors | completed | Phase 2 | 262 | Children's Oncology GroupNETWORK | 5 | Nov 20, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT06175273 | Pediatric Oncology Nutrition Intervention Trial(POINT) | completed | Phase 2 / Phase 3 | 19 | Corey HawesOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT00357565 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | completed | Phase 2 | 34 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT04325841 | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 2 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT00780494 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT01553149 | Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 4 | Jan 7, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT06677853 | Timolol Maleate Gel for the Treatment of Infantile Hemangioma | completed | Phase 2 / Phase 3 | 168 | Auson Pharmaceuticals Inc.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03579602 | Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery | completed | Phase 2 / Phase 3 | 118 | Blaze Bioscience Inc.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT02155920 | Everolimus for Children With Recurrent or Progressive Ependymoma | completed | Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT02913612 | Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)(TIM01) | completed | Phase 2 | 105 | Kanecia Obie ZimmermanOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT04508400 | Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients | completed | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05045443 | Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia(CurcumPedALL) | completed | Phase 2 | 30 | Ain Shams UniversityOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT00167219 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT04659421 | Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas | completed | Phase 2 | 60 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04562792 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 1 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05636566 | Comparing TIVA Using Propofol or Dexmedetomidine Versus Sevoflurane During Anaesthesia of Children Undergoing Bone-Marrow Aspiration | completed | Phase 2 / Phase 3 | 60 | Alexandria UniversityOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT01700946 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | completed | Phase 2 | 80 | St. Jude Children's Research HospitalOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT00432094 | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | completed | Phase 2 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT00003458 | Antineoplaston Therapy in Treating Children With Brain Tumors | completed | Phase 2 | 34 | Burzynski Research InstituteOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | completed | Phase 2 | 62 | Children's Oncology GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT01780662 | Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Oct 28, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01010308 | Nadolol for Proliferating Infantile Hemangiomas | completed | Phase 2 | 20 | The Hospital for Sick ChildrenOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | completed | Phase 2 / Phase 3 | 361 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT00860574 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT01363128 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jul 29, 2026source: clinicaltrials